drugset / Trial / NCT01023295

Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)

NCT01023295

Phase 2 Completed 20 enrolled Mateon Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to examine effects of fosbretabulin tromethamine (fosbretabulin) on PCV as reflected by a change from baseline in the number of polypoid lesions on indocyanine green angiography (ICGA).

Timeline

Start
2009-07
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject fosbretabulin Small molecule 15 mg/m2 Intravenous
Subject fosbretabulin Small molecule 25 mg/m2 Intravenous
Subject fosbretabulin Small molecule 35 mg/m2 Intravenous
Subject fosbretabulin Small molecule 45 mg/m2 Intravenous